Nov 5, 6:02 AM ET
Prestige Consumer Healthcare reported fiscal second-quarter 2027 revenue of $336.3 million, up 22.7% from a year earlier, with adjusted diluted EPS of $1.13 versus $1.07. The company lowered its fiscal 2027 revenue and adjusted EPS guidance, citing variable Clear Eyes production at its Pillar5 facility, which is expected to reduce product availability and revenue in the second half.
- Q2 reported revenue $336.3 million, up 22.7%; organic revenue fell 1.6% excluding acquisitions and foreign currency
- Q2 GAAP diluted EPS $0.53 versus $0.86 a year earlier; adjusted diluted EPS $1.13 versus $1.07
- Fiscal 2027 revenue outlook lowered to $1,280 million to $1,290 million from $1,290 million to $1,315 million
- Fiscal 2027 adjusted diluted EPS outlook lowered to $4.48 to $4.55 from $4.55 to $4.65
Read the filing on SEC.gov ↗
Aug 14, 4:03 PM ET
On August 10, 2026, Senior Vice President, Operations Jeffrey Zerillo notified Prestige Consumer Healthcare Inc. that he will retire from that role and all other positions he holds with the company, effective August 14, 2026. The filing does not name a successor or describe any separation or compensation terms, so shareholders have limited information on how the operations role will be filled.
- Retirement notice given August 10, 2026
- Retirement effective August 14, 2026, covering the SVP Operations role and all other positions held
- Filing signed by Christine Sacco, Chief Financial Officer and Chief Operating Officer
- No successor or separation terms disclosed in the filing
Read the filing on SEC.gov ↗
Aug 6, 6:04 AM ET
Prestige Consumer Healthcare reported fiscal first-quarter 2027 revenue of $265.7 million, up 6.5%, with organic growth of 3.2%. GAAP diluted EPS fell to $0.61 from $0.95, while adjusted diluted EPS rose to $0.98 from $0.95 after excluding acquisition costs and Pillar5 facility remediation costs. The company raised its fiscal 2027 revenue and EPS outlook, which it said reflects only the addition of the Breathe Right and LaCorium acquisitions.
- Q1 revenue $265.7 million, up 6.5% from $249.5 million; organic revenue growth 3.2%
- GAAP net income $29.2 million, or $0.61 per diluted share, versus $47.5 million, or $0.95, a year earlier
- Adjusted diluted EPS $0.98 versus $0.95; adjustments include $12.8 million of acquisition costs and $7.1 million of Pillar5 remediation costs
- Fiscal 2027 revenue outlook raised to $1,290 to $1,315 million from $1,100 to $1,121 million; adjusted diluted EPS outlook raised to $4.55 to $4.65 from $4.42 to $4.51
Read the filing on SEC.gov ↗
Jul 15, 4:03 PM ET
Prestige Brands, a wholly owned subsidiary of Prestige Consumer Healthcare, issued $400.0 million of 6.250% senior notes due July 15, 2034, under an indenture dated July 15, 2026. The notes are unsecured and guaranteed by the parent company, adding $400 million of long-term debt that shareholders will carry alongside existing obligations.
- Principal amount: $400.0 million of 6.250% senior notes due July 15, 2034
- Interest payable January 15 and July 15 each year, starting January 15, 2027
- Parent company and certain domestic subsidiaries guarantee the notes on an unsecured senior basis
- Change of Control triggers an offer to repurchase at 101% of principal; notes may be redeemed from July 15, 2029
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.